Status:
RECRUITING
Propranolol in Primary Progressive Aphasia
Lead Sponsor:
University of Missouri-Columbia
Conditions:
Aphasia, Primary Progressive
Eligibility:
All Genders
50+ years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressiv...
Eligibility Criteria
Inclusion
- 1\. Age: 50 and older
- 2\. Primary Progressive Aphasia diagnosis
- 3\. Native English speaker
Exclusion
- 1\. Unable to provide consent
- 2\. Taking alpha 2 agonists (clonidine and guanfacine)
- 3\. Other major psychological or neurological diagnosis
- 4\. Major head trauma that contributed to their condition
- 5\. Allergic reaction to adhesives
- 6\. Uncorrected vision/hearing impairments
- 7\. Diabetes
- 8\. Reactive airway disease
- 9\. Untreated hypothyroidism
- 10\. Bradyarrhythmia
- 11\. Unexplained syncope
- 12\. Pregnancy (assessed verbally on the days of MR imaging)
- 13\. Drugs that interact with propranolol, such as alpha 2 agonists
- 14\. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.
Key Trial Info
Start Date :
January 13 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06066710
Start Date
January 13 2025
End Date
December 1 2027
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Missouri-Columbia
Columbia, Missouri, United States, 65212